An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate

被引：0
|
作者：
T Leguay
V Desplat
V Lagarde
G Marit
J Reiffers
F-X Mahon
机构：
[1] Laboratoire hématopoïèse leucémique et cible thérapeutique INSERM E0217,
[2] Université Victor Segalen Bordeaux II,undefined
[3] Service des Maladies du Sang,undefined
[4] Hôpital du Haut-Lévèque,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1671 / 1673
页数：2
相关论文
共 50 条
  • [31] ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts
    Quigley, Neil B.
    Henley, Donald C.
    Hubbard, Roger A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (05): : 475 - 476
  • [32] BCR-ABL expression levels determine the rate of development of resistance to imatinib mesylate (Gleevec).
    Barnes, DJ
    Goldman, JM
    Melo, JV
    BLOOD, 2003, 102 (11) : 415A - 415A
  • [33] High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.
    Vigneri, Paolo G.
    Stagno, Fabio
    Stella, Stefania
    Cupri, Alessandra
    Forte, Stefano
    Massimino, Michele
    Antolino, Agostino
    Caracciolo, Clementina
    Nocilli, Laura
    Impera, Stefana
    Musolino, Caterina
    Turri, Diamante
    Russo, Mario
    Tomaselli, Carmen
    Rizzo, Michele
    Musso, Maurizio
    Morabito, Fortunato
    Levato, Luciano
    Manzella, Livia
    Mueller, Martin
    Di Raimondo, Francesco
    BLOOD, 2012, 120 (21)
  • [34] EFFECT OF IMATINIB MESYLATE ON PLATELET AGGREGATION ABNORMALITIES IN BCR-ABL plus CML PATIENTS
    Mogalluru, S. U.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 570 - 570
  • [35] Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines
    Desplat, V
    Belloc, F
    Lagarde, V
    Boyer, C
    Melo, JV
    Reiffers, J
    Praloran, V
    Mahon, FX
    CANCER, 2005, 103 (01) : 102 - 110
  • [36] TOXICITY OF BCR-ABL TYROSINE KINASE INHIBITORS: IMATINIB, DASATINIB AND NILOTINIB
    Sanchez Rocio, Pardo
    Arce Maria, Vuelta
    Mari Pau, Monfort Cervera
    Parada Lucia, Sanchez
    Tardon Leticia, Sanchez-Pacheco
    Vicente Teresa, Aguilella
    ATENCION FARMACEUTICA, 2012, 14 (05): : 343 - 354
  • [37] BCR-ABL TYROSINE KINASE MUTATIONS IN IMATINIB MESYLATE RESISTANT CML PATIENTS FROM OMAN: SINGLE CENTRE EXPERIENCE
    Pathare, V.
    Alkindi, S.
    Al Zadjali, A.
    Al Farsi, S.
    Huneini, N.
    Zia, B.
    Dennison, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 576 - 576
  • [38] Inhibition of Bcr-Abl kinase activity with imatinib induces poly (ADP) ribosylation in Bcr-Abl positive hematopoietic cells.
    Moehring, A
    van der Kuip, H
    Wohlbold, L
    Duyster, J
    Aulitzky, WE
    BLOOD, 2003, 102 (11) : 202B - 202B
  • [39] BCR-ABL kinase domain mutations & SNPs in imatinib resistant or intolerant chronic myeloid leukaemia patients
    O'Connor, Lisa M.
    Langabeer, Stephen
    McCann, Shaun R.
    Conneally, Eibhlin
    BLOOD, 2007, 110 (11) : 699A - 700A
  • [40] Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib
    Press, Richard D.
    Willis, Stephanie G.
    Laudadio, Jennifer
    Mauro, Michael J.
    Deininger, Michael W. N.
    BLOOD, 2008, 112 (11) : 405 - 405
12345